Breaking news

Greenland’s Tourism Boom: Trump Effect And New Airports Drive Growth

Greenland is witnessing a surge in tourism, fueled by renewed international attention following remarks by former U.S. President Donald Trump and a wave of new infrastructure projects. The opening of Nuuk’s new international airport has significantly improved access, with direct flights from New York set to begin in June.

Key Facts

  • 14% rise in international arrivals: Statistics Greenland reported a sharp increase in January year-on-year.
  • Hotel stays surged: 355,000 nights recorded last year, up from 210,000 in 2014.
  • Nuuk Airport opened in November, streamlining travel and bypassing layovers in Copenhagen and Kangerlussuaq.
  • Ilulissat and Qaqortoq to get international airports, further boosting accessibility.
  • Three-quarters of tour operators saw increased bookings after Nuuk Airport’s opening.

The Bigger Picture

Greenland’s tourism momentum comes amid U.S. interest in the Arctic island’s rare earth minerals, critical for high-tech industries. While Trump’s idea of acquiring Greenland sparked controversy, it undeniably placed the region in the global spotlight. The country now aims to diversify its economy—currently 95% dependent on fishing—by leveraging tourism and mining.

With breathtaking glaciers, deep fjords, and a rich Inuit cultural heritage, Greenland’s tourism industry is poised for unprecedented growth.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

eCredo
Aretilaw firm
The Future Forbes Realty Global Properties
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter